News | Thrombectomy Devices | March 08, 2016

SITS Open Stroke Trial to Include pREset Thrombectomy Device

Trial protocol is designed to compare mechanical thrombectomy with concurrent medical management alone for stroke treatment

SITS Open trial, mechanical thrombectomy devices. pREset, stroke treatment

March 8, 2016 — phenox GmbH announced participation in the SITS Open clinical trial, where pREset and pREset LITE thrombectomy devices have been included in the study device portfolio. pREset is one of only three devices to be used in the study.

Stroke is the second leading cause of death worldwide and the most common cause of adult disability in the western world. Ischemic stroke, caused by a blocked artery, is the most common type of stroke and it takes only minutes without oxygen for brain damage to occur and more brain cells die every minute that flow is blocked. The aim of physicians is to restore blood flow by opening the blocked artery as quickly as possible, thereby enhancing the patient’s survivability and preventing long lasting disability.

The positive outcomes of recent randomized clinical trials for mechanical thrombectomy, such as MR CLEAN, ESCAPE, EXTEND IA and SWIFT PRIME, have renewed interest in studies enrolling a large number of patients. The SITS Open protocol is designed to provide a higher level of evidence for mechanical thrombectomy through a direct comparison between mechanical thrombectomy and a concurrent control of medical management alone.

The Department of Neuroscience at Karolinska Institute, Stockholm, Sweden, is sponsoring the open, prospective, international, multicenter, controlled clinical trial. The protocol calls for enrolling 600 patients in total, 300 in each arm. Patients enrolled in the treatment arm will be done so at centers that currently perform thrombectomy for stroke and fulfill the quality and training criteria for neuro-interventions. Patients in the control arm will be enrolled by clinics that offer IV thrombolysis and neither practice thrombectomy nor refer patients with ischemic stroke to other clinics where thrombectomy is offered.

For more information: www.phenox.net


Related Content

News | Thrombectomy Devices

June 16, 2025 – Penumbra, Inc. recently announced the completion of enrollment in the STORM-PE clinical trial. This ...

Home June 16, 2025
Home
News | Thrombectomy Devices

March 24, 2025 — Imperative Care, Inc. recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ...

Home March 24, 2025
Home
News | Thrombectomy Devices

Penumbra recently launched its Element Vascular Access System, a laser-cut hypotube sheath designed for venous ...

Home January 30, 2025
Home
News | Thrombectomy Devices

Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary ...

Home November 07, 2024
Home
News | Thrombectomy Devices

Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Food and Drug Administration (FDA) has ...

Home September 24, 2024
Home
News | Thrombectomy Devices

Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the ...

Home September 10, 2024
Home
News | Thrombectomy Devices

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
Feature | Thrombectomy Devices | By Global Market Insights

The global thrombectomy devices market is poised to experience substantial expansion, owing to the emergence of ...

Home June 27, 2022
Home
News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
News | Thrombectomy Devices

November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter ...

Home November 12, 2021
Home
Subscribe Now